Fundraising FoxHemex Health
Portland, US · Founded 2016 · Oregon corporation · 5 known investors
Find your way into Hemex Health
Sign up to see every warm intro you have to Hemex Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Hemex Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Hemex Health develops and commercializes the Gazelle diagnostic platform, including point-of-care readers and tests for conditions such as sickle cell disease and hemoglobin variants. It targets clinicians, patients, and public health programs in emerging and resource-limited markets, with significant operations and manufacturing in India.
Founders & leadership
Hemex Health was founded in 2016 by Patricia White Seminario, Peter Galen, and Patti White.
PW
Patricia White SeminarioCo-founder
PG
Peter GalenCo-founder · Chief Innovation OfficerHe was CTO at Inovise Medical for a decade before serving as CEO of CardioDigital and Quantum Catch and as President and CEO of Fastrack Products. He also spent years as Managing Partner at Asia LifeSciences Venture Consulting, co-founded The Mangrove Fund, and consulted for Welch Allyn as Managing Director for emerging markets.
PW
Patti WhiteChief Executive Officer, Co-FounderShe previously founded and led Inovise Medical as CEO for over a decade, and served as Chief Commercial Officer at Brien Holden Vision Diagnostics, VP and General Manager of the Physician Direct Business Unit at RS Medical, and Managing Director at Medical Market Strategy. Her career began at Hewlett-Packard, where she held executive roles in marketing, R&D and international operations from 1984 to 1997.
DB
Daren BledsoeSr. VP, Engineering & OperationsDaren Bledsoe is Senior VP of Engineering and Operations at Hemex Health, where he has worked for over 8 years overseeing engineering development and manufacturing of the Gazelle diagnostic platform in India. He holds a BS in Electrical Engineering from Washington State University and brings over 40 years of experience in medical device and semiconductor development, including prior roles in engineering, manufacturing, and operations at companies including Hewlett Packard.
GV
Gerrit van RoekelVP, Business DevelopmentGerrit van Roekel is VP of Business Development at Hemex Health, a developer of point-of-care diagnostic tests for conditions including sickle cell disease and hemoglobin variants. He has worked in life sciences business development, licensing, and strategic partnerships across global markets.
UG
Umut GurkanChief Scientist, MicrofluidicsUmut Gurkan is the Wilbert J. Austin Professor of Engineering at Case Western Reserve University, where he leads the Case Biomanufacturing and Microfabrication Laboratory; he holds a Ph.D. from Purdue University, completed postdoctoral training at Harvard-MIT, and has published over 110 papers and holds 18 US patents in microfluidic diagnostics and blood disorder research.
NS
Nikki SiddiquiChief Financial OfficerNikki Siddiqui is Chief Financial Officer of Hemex Health, which develops point-of-care diagnostic platforms for conditions like sickle cell disease in emerging markets. She has prior experience in medical device and defense contracting finance, and holds a Master's degree in Tax Law from Portland State University.
PK
Prashant KhadkeManaging Director, India Commercial Operations
PL
Paul LongoVP-Product DevelopmentPaul Longo brings 25 years of medtech experience, including roles as VP of R&D at RevMedx (a defense-funded wound treatment startup), Account Director at Ziba Design's healthcare practice, and product designer at Stryker where he worked on surgical devices and navigation systems. At Hemex Health, he leads product development for the Gazelle diagnostic platform.
PA
Prakash AgarwalNamed on SEC filing
MU
Mohan UttarwarNamed on SEC filing
SM
Susan MorgenszternNamed on SEC filing
Investors · 5
CWRU Technology Ventureslisted by CWRU Technology VenturesCleveland · $50K – $250K
How we know: CWRU Technology Ventures's portfolio page · Not right? Tell us
Elevate Capitallisted by Elevate CapitalPortland · $2M – $25M
How we know: the VCSheet dataset · Not right? Tell us
Ideashiplisted by IdeashipPortland
How we know: Ideaship's portfolio page · press coverage · funding news · Not right? Tell us
Impact India Investment Partnerslisted by Impact India Investment PartnersMumbai · $150K – $1M
How we know: Impact India Investment Partners's portfolio page · Not right? Tell us
Portland Seed Fundlisted by Portland Seed FundPortland · $25K
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 2 of 3 rounds · 2016–2018
▶$930KraisedMar 2018 · 27 investors · OtherRule 506(b)
▶$930KraisedMar 2018 · 27 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Annette MuleeDirector
- Mohan UttarwarDirector
- Peter GalenExecutive Officer, Director
- Patricia White SeminarioExecutive Officer, Director
- Prakash AgarwalDirector
- Susan MorgenszternDirector
- Offering amount
- $930K
- Amount sold
- $930K
- First sale
- Jan 2018
- Incorporated
- Corporation, Oregon, 2016
- Federal exemptions
- 06b
▶$27.3KofferedMar 2018 · 1 investors · OtherRule 506(b)
▶$27.3KofferedMar 2018 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mohan UttarwarDirector
- Peter GalenExecutive Officer, Director
- Susan MorgenszternDirector
- Patricia SeminarioExecutive Officer, Director
- Prakash AgarwalDirector
- Annette MuleeDirector
- Offering amount
- $27.3K
- First sale
- Jan 2018
- Incorporated
- Corporation, Oregon, 2016
- Federal exemptions
- 06b
▶$3MraisedDec 2017 · 46 investors · Other TechnologyRule 506(b)
▶$3MraisedDec 2017 · 46 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Prakash AgarwalDirector
- Mohan UttarwarDirector
- Patricia White SeminarioExecutive Officer, Director, Promoter
- Peter GalenExecutive Officer, Director, Promoter
- Susan MorgenszternDirector
- Annette MuleeDirector, Promoter
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Sep 2016
- Incorporated
- Corporation, Oregon, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Companies working in the same space as Hemex Health.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $225.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Hemex Health do?
- Hemex Health develops and commercializes the Gazelle diagnostic platform, including point-of-care readers and tests for conditions such as sickle cell disease and hemoglobin variants. It targets clinicians, patients, and public health programs in emerging and resource-limited markets, with significant operations and manufacturing in India.
- Who founded Hemex Health?
- Hemex Health was founded by Patricia White Seminario, Peter Galen, Patti White in 2016.
- Who are Hemex Health's investors?
- Hemex Health's investors include CWRU Technology Ventures, Elevate Capital, Ideaship, Impact India Investment Partners, Portland Seed Fund.
- How much funding has Hemex Health raised?
- Hemex Health has disclosed $3.9M raised across 2 of its 3 known rounds.
- Where is Hemex Health headquartered?
- Hemex Health is headquartered in Portland, US.